中文摘要：

目的 探讨曲美他嗪对经皮冠状动脉介入治疗（PCI）术相关心肌缺血再灌注损伤及预后的影响.方法 选择94例择期PCI术冠心病患者,随机分为研究组和对照组,各47例,研究组在对照组常规治疗基础上于术前3d开始口服曲美他嗪至术后维持,比较两组手术前后血清cTnI、CK-MB、MDA、CRP水平,术后12个月随访心血管不良事件发生情况.结果 两组术后血清cTnI、CK-MB、MDA、CRP水平均显著升高（P＜0.05）,但研究组术后各时点血清cTnI、CK-MB、MDA、CRP水平均显著低于对照组（P＜0.05）.经Kaplan-Meier生存曲线法计算,研究组和对照组术后12个月无心血管不良事件,生存率分别为85.23％和64.39％ （P ＜0.05）.研究组患者无明显不良反应.结论 曲美他嗪对PCI术缺血再灌注造成的心肌损伤有保护作用,可减少近期心血管不良事件发生,长期服用安全性好.

英文摘要：

Objective To investigate the effect of trimetazidine on PCI, myocardial ischemia and reperfusion-related injury and prognosis. Methods A total of 94 cases of coronary heart disease patients undergoing elective PCI were randomly divided into study group and the control group , 47 cases in the control group, the study group on the basis of conventional therapy before surgery 3d start giving oral trimetazidine to maintain postoperative two groups were com- pared before and after surgery serum cTnI, CK-MB, MDA, CRP levels and after 12 months follow-up of cardiovascular adverse events were observed. Results The postoperative serum cTnI, CK-MB, MDA, CRP levels were significantly higher （P 〈0.05）, but the study group at all time points in the postoperative serum cTnI, CK-MB, MDA, CRP levels were significantly lower in the control group （P 〈0.05）. The Kaplan-Meier survival curve method , the study group and the control group after 12 months without cardiovascular adverse event rates were 85.23% and 64.39% , study group had no adverse cardiovascular event-free survival were significantly higher （P 〈0.05）. Study group patients with no significant adverse reactions. Conclusion Trimetazidine has a protective effect on PCI myocardial ischemia-reperfusion injury, reducing the near future to improve the prognosis of cardiovascular adverse events, long-term use good security.